Project Grant R43AI140807

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $185,513 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tulane University to develop an enterotoxigenic Escherichia coli (ETEC) multivalent subunit vaccine using outer membrane vesicles. The project aims to establish anti-ETEC immunity in the gastrointestinal tract to neutralize enterotoxins and block bacterial colonization. The research will test the hypothesis that...

This $304,742 Project Grant awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel low-cost intradermal delivery platform for nucleic acid vaccines. The project aims to create a handheld pen device that can deliver electrical pulses through microelectrodes to create temporary pores in skin cells, allowing direct vaccine delivery to immune cells without the need for lipid nanoparticles (LNPs) or...

This Project Grant award of $458,250.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a VP4-based pseudovirus nanoparticle rotavirus vaccine for oral immunization. The award will fund research to create a non-replicating rotavirus vaccine candidate called S-VP4E, which consists of a calicivirus inner shell and multiple rotavirus spikes (VP4E) on the surface. This...

This $650,000 Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, supports research and development for a next generation probiotics-based platform technology to enable oral delivery of peptide and protein therapeutics. Specifically, the project aims to (1) develop an antibiotic-resistance-free expression system for stable, high-level production of therapeutic peptides in Lactobacillus probiotic strains, (2) create inducible...

This $335,410 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of a needle-free microneedle array patch (MAP) for delivering a GLP-1 receptor agonist to treat type 2 diabetes. The grant recipient, Vaxess Technologies, Inc., is a biotechnology company specializing in innovative MAP technologies for drug and vaccine...

This $300,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel vaccine candidates for cryptosporidiosis, a leading cause of diarrhea and malnutrition in children in low- and middle-income countries. The grantee, Immport Therapeutics Inc. (doing business as Antigen Discovery Inc.), will formulate cryptosporidium proteins and a mucosal...

This $314,363 Project Grant was awarded on September 11, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research grant program (CFDA 93.855) to Via Therapeutics, LLC, a for-profit company based in Austin, Texas. The grant supports the development of a microneedle-based mRNA flu vaccine for transcutaneous immunization. The goal is to create a stable, patient-friendly influenza vaccine delivered through the skin rather than by...

This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 in funding to Immuno Nano Med, Inc. to demonstrate the feasibility of producing a novel room-temperature-stable, dry-powder inhalable influenza vaccine. The goal is to develop an innovative, next-generation influenza vaccine technology that can promote public health by eliminating the pain points of current flu vaccines, such as the need...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), with a CFDA number of 93.855, provides $314,347 in funding to Gateway Bio Inc. for the period from September 23, 2025 to August 31, 2026. The project aims to develop a new lipid nanoparticle (LNP) delivery system for mRNA payloads that uses a proprietary polyethylene glycol (PEG) alternative called POEGMA. This novel LNP is intended to address concerns around PEG-related allergies and reduced...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $242,250.00 to researchers at the University of Virginia to develop a vaccine against cryptosporidiosis, a common cause of diarrheal disease in sub-Saharan Africa and Asia. The goal is to create a liposomal vaccine formulation that stimulates both cellular and humoral immunity targeting the extracellular and intracellular life stages of the...